Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | LCK | P06239 | 1/20 | 0.50 |
| ▸ | PPARD | Q03181 | 1/20 | 0.50 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.50 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.43 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4587471 | 0.98 | GPR84 (0.53) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL2373767 | 0.98 | GPR84 (0.53) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL626862 | 0.98 | GPR84 (0.53) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL7134892 | 0.96 | GPR84 (0.55) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL19066785 | 0.96 | GPR84 (0.55) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL28046653 | 0.96 | GPR84 (0.55) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL2492300 | 0.96 | GPR84 (0.55) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL17685264 | 0.94 | GPR84 (0.57) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL9770059 | 0.94 | GPR84 (0.57) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL268638 | 0.94 | GPR84 (0.57) | GPR84FFAR1MAPTLCKPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230277571-A1 | THERAPEUTIC USES OF PHARMACEUTICAL COMPOSITIONS COMPRISING CYCLIC BORONIC ACID ESTER DERIVATIVES | MELINTA SUBSIDIARY CORP. | 2023-09-07 | — | — | US | disclosed |
| EP-3666778-B1 | CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF | MELINTA THERAPEUTICS INC (US) | 2021-11-10 | — | — | EP | disclosed |
| US-11090319-B2 | Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives | MELINTA SUBSIDIARY CORP. (US) | 2021-08-17 | — | — | US | disclosed |
| US-20200222434-A1 | THERAPEUTIC USES OF PHARMACEUTICAL COMPOSITIONS COMPRISING CYCLIC BORONIC ACID ESTER DERIVATIVES | MELINTA SUBSIDIARY CORP. | 2020-07-16 | — | — | US | disclosed |
| EP-3666778-A1 | A CRYSTALLINE CYCLIC BORONIC ACID ESTER DERIVATIVE, METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF | Rempex Pharmaceuticals, Inc. (US) | 2020-06-17 | — | — | EP | disclosed |
| US-10639318-B2 | Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives | REMPEX PHARMACEUTICALS, INC. (US) | 2020-05-05 | — | — | US | disclosed |
| EP-3412676-B1 | CYCLIC BORONIC ACID ESTER DERIVATIVES, METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF | REMPEX PHARMACEUTICALS INC (US) | 2020-02-12 | — | — | EP | disclosed |
| US-20190076449-A1 | THERAPEUTIC USES OF PHARMACEUTICAL COMPOSITIONS COMPRISING CYCLIC BORONIC ACID ESTER DERIVATIVES | MELINTA SUBSIDIARY CORP. | 2019-03-14 | — | — | US | disclosed |
| US-10183034-B2 | Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives | REMPEX PHARMACEUTICALS, INC. (US) | 2019-01-22 | — | — | US | disclosed |
| EP-3412676-A1 | METHOD FOR THE PREPARATION OF CYCLIC BORONIC ACID ESTER DERIVATIVES | Rempex Pharmaceuticals, Inc. (US) | 2018-12-12 | — | — | EP | disclosed |
| US-20160220591-A1 | CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF | MELINTA SUBSIDIARY CORP. | 2016-08-04 | — | — | US | disclosed |
| EP-2814483-A2 | METHODS OF TREATING BACTERIAL INFECTIONS | Rempex Pharmaceuticals, Inc. (US) | 2014-12-24 | — | — | EP | disclosed |
| WO-2013122888-A2 | METHODS OF TREATING BACTERIAL INFECTIONS | REMPEX PHARMACEUTICALS, INC. (US) | 2013-08-22 | — | — | WO | disclosed |
| EP-2603514-A1 | CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF | Rempex Pharmaceuticals, Inc. (US) | 2013-06-19 | — | — | EP | disclosed |
| WO-2012021455-A1 | CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF | REMPEX PHARMACEUTICALS, INC. (US) | 2012-02-16 | — | — | WO | disclosed |
| WO-2008046554-A1 | PROPYLALKYL ESTERS AS OIL PHASE IN BOREHOLE TREATMENT COMPOSITIONS | COGNIS OLEOCHEMICALS GMBH (DE) | 2008-04-24 | — | — | WO | disclosed |
| EP-1914288-A1 | Propylalkyl esters as oleaginous phase in well treatment fluids | Cognis Oleochemicals GmbH (DE) | 2008-04-23 | — | — | EP | disclosed |
| EP-0550779-B1 | Cosmetic and dermatologic composition containing diol diesters | NESTLE SA (CH) | 1995-10-18 | — | — | EP | disclosed |
| EP-0441992-B1 | Process for preparing salolein and cosmetic compositious therewith | NESTLE SA (CH) | 1995-01-18 | — | — | EP | disclosed |
| EP-0550779-A1 | Cosmetic and dermatologic composition containing diol diesters | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 1993-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10183034-B2 | Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives | BCL6B, BCL6, SLC10A2 | GPR84 3014/4885FFAR1 1899/4885MAPT 4088/4885 |
| US-20160220591-A1 | CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF | BCL6B, BCL6, BCL9 | GPR84 2042/4885FFAR1 1281/4885MAPT 4223/4885 |
| US-20200222434-A1 | THERAPEUTIC USES OF PHARMACEUTICAL COMPOSITIONS COMPRISING CYCLIC BORONIC ACID ESTER DERIVATIVES | BCL6B, BCL6, SLC10A2 | GPR84 3014/4885FFAR1 1899/4885MAPT 4088/4885 |
| US-10639318-B2 | Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives | BCL6B, BCL6, SLC10A2 | GPR84 3014/4885FFAR1 1899/4885MAPT 4088/4885 |
| US-20190076449-A1 | THERAPEUTIC USES OF PHARMACEUTICAL COMPOSITIONS COMPRISING CYCLIC BORONIC ACID ESTER DERIVATIVES | BCL6B, BCL6, SLC10A2 | GPR84 3014/4885FFAR1 1899/4885MAPT 4088/4885 |
| US-11090319-B2 | Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives | BCL6B, BCL6, SLC10A2 | GPR84 3014/4885FFAR1 1899/4885MAPT 4088/4885 |
| US-20230277571-A1 | THERAPEUTIC USES OF PHARMACEUTICAL COMPOSITIONS COMPRISING CYCLIC BORONIC ACID ESTER DERIVATIVES | BCL6B, BCL6, SLC10A2 | GPR84 3014/4885FFAR1 1899/4885MAPT 4088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.